| Therapeutic | Ravagalimab |
| Target | CD40 |
| Heavy Chain | EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS |
| Light Chain | DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK |
| 100% seqID Fv Structure | 6pe7 [Fvs: HL], 6pe8 [Fvs: AB, HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6pe7 [Fvs: HL] |
| 100% seqID Structure | 6pe8 [Fvs: AB, HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Phase-II |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2017 |
| INN Year Recommended | 2018 |
| Companies Involved | AbbVie |
| Conditions Approved | na |
| Conditions Active | Ulcerative colitis |
| Conditions Discontinued | Crohn's disease |
| Notes |
